Waivers for Conflicts of Interest for the September 19, 2017 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
Disclaimer
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.
Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007. This provision was repealed, effective October 1, 2007, by the FDA.
Ronald Bukowski, M.D.
- 18 U.S.C. 208(b)(3) Waiver for the September 19, 2017 Meeting of the Oncologic Drugs Advisory Committee (Bukowski)
- Disclosure Document for the September 19, 2017 Meeting of the Oncologic Drugs Advisory Committee (Bukowski)